Patent US4795803A successfully refreshed from Google Patents.
US4795803A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Adhesin antigens, antibodies and DNA fragment encoding the antigen, methods and means for diagnosis and immunization etc.
Assignee: Syn-Tek AB
•
Filing: 1985-05-02
•
Granted: 1989-01-03
•
Expires: 2005-05-02
Abstract
Abstract An antigen which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunogenically active form, antibodies against which determinant react with the adhesion polypeptide produced by pathogenic adhesin-forming bacteria which adhere to mammalian tissue, antibodies against such antigen, and DNA expressing, as a principal gene product thereof, such antigen.
Inventors
- 👤 Frederick C. Lindberg
- 👤 Bjorn O. Lund
- 👤 Britt M. Baga
- 👤 Mari E. Norgren
- 👤 Mikael Goransson
- 👤 Bernt E. Uhlin
- 👤 Jan S. Normark
- 👤 David L. Lark
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 02:50
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/195; C07K14/24; A; A61; A61K; A61K39/00; A61K39/02; A61K39/025; A61K39/0258; A61P; A61P31/00; A61P31/04; C07K14/21; C07K14/22; C07K14/235; C07K14/245; C07K14/305; C07K14/31; C07K14/315; C07K2319/00; C07K2319/33; C07K2319/40; Y; Y10; Y10S; Y10S435/00; Y10S435/82; Y10S530/00; Y10S530/806; Y10S530/82; Y10S530/825
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
58 words
An isolated antigen which comprises a pilus component distinct from pilin and substantially free from other components of the pilus, an immunogenically active subsequence of said component or a precursor for said component which is convertible to an immunologically active form, said antigen being one which elicits antibodies inhibiting the adhesion of pathogenic adhesin-forming bacteria to mammalian tissue.
Claim 2
Dependent Claim
58 words
An isolated antigen which comprises a pilus component distinct from pilin and substantially free from other components of the pilus, an immunogenically active subsequence of said component or a precursor for said component which is convertible to an immunologically active form, said antigen being one which elicits antibodies inhibiting the adhesion of pathogenic adhesin-forming bacteria to mammalian tissue.
Claim 3
Dependent Claim
30 words
An antigen according to claim 1 which comprises an amino acid sequence of at least 5 amino acids and up to the entire amino acid sequence of the pilus component.
Claim 4
Dependent Claim
17 words
An antigen according to claim 1 which binds to carbohydrate or protein receptors on mammalian tissue cells.
Claim 5
Dependent Claim
14 words
An antigen according to claim 3 which binds to a digalactoside-containing glycolipid or glycoprotein.
Claim 6
Dependent Claim
14 words
An antigen according to claim 1 which is derived from a pathogenic pilus-forming bacterium.
Claim 7
Dependent Claim
32 words
An antigen according to claim 5 in which the bacterium is a uropathogenic or enteropathogenic strain of Escherichia coli, Neisseria gonorrhoeae, Neisseria meningiditis; Neisseria catarrhalis, Pseudomonas spp., Moraxella spp., or Bordetella spp.
Claim 8
Dependent Claim
18 words
An antigen according to claim 6 in which the pathogenic strain of E. coli is a uropathogenic strain.
Claim 9
Dependent Claim
22 words
An antigen according to claim 1 which has the following amino acid sequence: Met-Lys-Lys-Ile-Arg-Gly-Leu-Cys-Leu-Pro-Val-Met-Leu-Gly-Ala-Val-Leu-Met-Ser-Gln-His-Val-His-Ala-Val-Asp-Asn-Leu-Thr-Phe-Arg-Gly-Lys-Leu-Ile-Ile-Pro-Ala-Cys-Thr-Val-Ser-Asn-Thr-Thr-Val-Asp-Trp-Gln-Asp-Val-Glu-Ile-Gln-Thr-Leu-Ser-Gln-Asn-GluyAsn-His-Glu-Lys Glu-Phe-Thr-Val-Asn-Met-Arg-Cys-Pro-Tyr-Asn-Leu-Gly-Thr-Met-Lys-Val-Thr-Ile-Thr-Ala-Thr-Asn-Thr-Tyr-Asn-Asn-Ala-Ile-Leu-Val-Gln-Asn-Thr-Ser-Asn-Thr-Ser-Ser-Asp-Gly-Leu-Leu-Val-Tyr-Leu-Tyr-Asn-Ser-Asn-Ala-Gly-Asn-Ile-Gly-Thr-Ala-Ile-Thr-Leu-Gly-Thr-Pro-Phe Thr-Pro-Gly-Lys-Ile-Thr-Gly-Asn-Asn-Ala-Asp-Lys-Thr-Ile-Ser-Leu-His-Ala-Lys-Leu-Gly-Tyr-Lys-Gly-Asn-Met-Gln-Asn-Leu-Ile-Ala-Gly-Pro-Phe-Ser-Ala-Thr-Ala-Thr-Leu-Val-Ala-Ser-Tyr-Ser or any immunogenically active subsequence thereof.
Claim 10
Dependent Claim
22 words
An antigen according to claim 1 which has the following amino acid sequence: Met-Ile-Arg-Leu-Ser-Leu-Phe-Ile-Ser-Leu-Leu-Leu-Thr-Ser-Val-Ala-Val-Leu-Ala-Asp-Val-Gln-Ile-Asn-Ile-Art-Gly-Asn-Val-Tyr-Ile-Pro-Pro-Cys-Thr-Ile-Asn-Asn-Gly-Gln-Asn-Ile-Val-Val-Asp-Phe-Gly-Asn-Ile-Asn-Pro-Glu-His-Val-Asp-Asn-Ser-Arg-Gly-Glu-Val-Thr-Lys-Thr Ile-Ser-Ile-Ser-Cys-Pro-Tyr-Lys-Ser-Gly-Ser-Leu-Trp-Ile-Lys-Val-Thr-Gly-Asn-Thr-Met-Gly-Gly-Gly-Gln-Asn-Asn-Val-Leu-Ala-Thr-Asn-Ile-Thr-His-Phe-Gly-Ile-Ala-Leu-Tyr-Gln-Gly-Lys-Gly-Met-Ser-Thr-Pro-Leu-Ile-Leu-Gly-Asn-Gly-Ser-Gly-Asn-Gly-Tyr-Gly-Val-T r-Ala-Gly-Leu-Asp-Thr-Ala-Arg-Ser-Thr-Phe-Thr-Phe-Thr-Ser-Val-Pro-Phe-Arg-Asn-Gly-Ser-Gly-Ile-Leu-Asn-Gly-Gly-Asp-Phe-Gln-Thr-Thr-Ala-Ser-Met-Ser-Met-Ile-Tyr-Asn or any immunogenically active subsequence thereof.
Claim 11
Dependent Claim
25 words
An antigen according to claim 1 which has the following amino acid sequence: Met-Lys-Lys-Trp-Phe-Pro-Ala-Phe-Leu-Phe-Leu-Ser-Leu-Ser-Gly-Gly-Asn-Asp-Ala-Leu-Ala-Gly-Trp-His-Asn-Val-Met-Phe-Tyr-Ala-Phe-Asn-Asp-Tyr-Leu-Thr-Thr-Asn-Ala-Gly-Asn-Val-Lys-Val-Ile-Asp-Gln-Pro-Gln-Leu-Tyr-Ile-Pro-Trp-Asn-Thr-Gly-Ser-Ala-Thr-Ala-Thr-Tyr-Tyr Ser-Cys-Ser-Gly-Pro-Glu-Phe-Ala-Ser-Gly-Val-Tyr-Phe-Gln-Glu-Tyr-Leu-Ala-Trp-Met-Val-Val-Pro-Lys-His-Val-Tyr-Thr-Asn-Glu-Gly-Phe-Asn-Ile-Phe-Leu-Asp-Val-Gln-Ser-Lys-Tyr-Gly-Trp-Ser-Met-Glu-Asn-Glu-Asn-Asp-Lys-Asp-Phe-Tyr-Phe-Phe-Val-Asn-Gly-Tyr-Glu-Trp-Asp Thr-Trp-Thr-Asn-Asn-Gly-Ala-Arg-Ile-Cys-Phe-Tyr-Pro-Gly-Asn-Met-Lys-Gln-Leu-Asn-Asn-Lys-Phe-Asn-Asp-Leu-Val-Phe-Arg-Val-Leu-Leu-Pro-Val-Asp-Leu-Pro-Lys-Gly-His-Tyr-Asn-Phe-Pro-Val-Arg-Tyr-Ile-Arg-Gly-Ile-Gln-His-His-Tyr-Tyr-Asp-Leu-Trp-Gln-Asp-His-Tyr-Lys Lys-Met-Pro-Tyr-Asp-Gln-Ile-Lys-Gln-Leu-Pro-Ala-Thr-Asn-Thr-Leu-Met-Leu-Ser-Phe-Asp-Asn-Val-Gly-Gly-Cys-Gln-Pro-Ser-Thr-Gln-Val-Leu-Ash-Ile-Asn-His-Gly-Ser-Ile-Val-Ile-Asp-Arg-Ala-Asn-Gly-Asn-Ile-Ala-Ser-Gln-Thr-Leu-Ser-Ile-Tyr-Cys-Asp-Val-Pro-Val-Ser-Val Lys-Ile-Ser-Leu-Leu-Arg-Asn-Thr-Pro-Pro-Ile-Tyr-Asn-Asn-Asn-Lys-Phe-Ser-Val-Gly-Leu-Gly-Asn-Gly-Trp-Asp-Ser-Ile-Ile-Ser-Leu-Asp-Gly-Val-Glu-Gln-Ser-Glu-Glu-Ile-Leu-Arg-Trp-Tyr-Thr-Ala-Gly-Ser-Lys-Thr-Val-Lys-Ile-Glu-Ser-Arg-Leu-Tyr-Gly-Glu-Glu-Gly-Lys-Arg Lys-Pro-Gly-Glu-Leu-Ser-Gly-Ser-Met-Thr-Met-Val-Leu-Ser-Phe-Pro or any immunologically active subsequence thereof.
References Cited (Backward Citations)
US4157390A
Cited
US4657849A
Cited
US4454117A
Cited
US4443431A
Cited
US4521334A
Cited
US4652448A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-01-03 | 1992-07-04 | 1993-01-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-01-03 | 1996-07-04 | 1997-01-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-01-03 | 2000-07-04 | 2001-01-03 | $7700.00 | Window Closed / Lapsed |